Nonmechanical Small Bowel Obstruction in a Patient on Zepbound Without a Surgical History: A Case Report.
Lorenz. Nicholas N; Stauffer. John J; Abouafech. Alex A; Mourad. Amia A; Bray. Kelvin K
Key Findings
- Dose escalation of tirzepatide was associated with a functional small bowel obstruction in a patient with no prior abdominal surgery
- The obstruction occurred without any other known risk factors, indicating a possible direct drug effect
- This case highlights a rare but severe gastrointestinal motility side effect of tirzepatide
Practical Outcomes
- When using tirzepatide, especially during dose increases, watch closely for any signs of abdominal pain, bloating, or vomiting that could signal a blockage. Consider a slower titration schedule and be ready to pause or stop the drug if severe GI symptoms appear, seeking medical attention promptly.
Summary
A 52‑year‑old woman taking tirzepatide (Zepbound) for weight loss developed a serious gut blockage after her dose was increased, even though she had never had abdominal surgery or other typical risk factors. This suggests the drug can sometimes cause dangerous gut‑movement problems on its own.
Abstract
We present the case of a 52-year-old woman who developed a functional small bowel obstruction despite having no history of abdominal surgery, prior bowel obstruction, or GI interventions. The only notable recent change in her medical history was a dose escalation of Zepbound (tirzepatide), a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide agonist prescribed for weight loss. This case raises concern about potential severe GI motility complications associated with Zepbound, particularly in the absence of conventional SBO risk factors.
Study Information
pubmed
2025
2025-08-21T00:00:00.000Z
10.7759/cureus.90657
1
13